---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345722"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-08-12T11:02:57+00:00"
generated_at: "2026-08-12T11:05:08.208205+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexeo Q2 net loss $25.9M; initiates LX2006 pivotal trial, gains RMAT for LX2020

## Summary
- Net loss $25.9M ($0.30/sh) vs $26.1M ($0.60/sh) YoY; R&D $19.0M vs $14.7M, G&A $9.0M vs $16.0M.
- Cash, equivalents and investments $234.2M expected to fund operations into 2028.
- First patient enrolled in SUNRISE-FA 2 pivotal trial for LX2006 in FA cardiomyopathy; topline data expected 2H 2027.
- FDA granted RMAT designation for LX2020 in PKP2-ACM; 12-month high-dose data update expected Q4 2026.
- LX2006 data published in JAMA Cardiology showing generally well tolerated with signs of efficacy in Phase I/II.

## SEC filing metadata
- accession: 0001193125-26-345722
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-08-12T11:02:57+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/0001193125-26-345722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345722
- JSON: https://secwatch.observer/filing/0001193125-26-345722.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.